Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.

The Lancet Oncology
Angela AlistarBoris Pasche

Abstract

Pancreatic cancer statistics are dismal, with a 5-year survival of less than 10%, and more than 50% of patients presenting with metastatic disease. Metabolic reprogramming is an emerging hallmark of pancreatic adenocarcinoma. CPI-613 is a novel anticancer agent that selectively targets the altered form of mitochondrial energy metabolism in tumour cells, causing changes in mitochondrial enzyme activities and redox status that lead to apoptosis, necrosis, and autophagy of tumour cells. We aimed to establish the maximum tolerated dose of CPI-613 when used in combination with modified FOLFIRINOX chemotherapy (comprising oxaliplatin, leucovorin, irinotecan, and fluorouracil) in patients with metastatic pancreatic cancer. In this single-centre, open-label, dose-escalation phase 1 trial, we recruited adult patients (aged ≥18 years) with newly diagnosed metastatic pancreatic adenocarcinoma from the Comprehensive Cancer Center of Wake Forest Baptist Medical Center (Winston-Salem, NC, USA). Patients had good bone marrow, liver and kidney function, and good performance status (Eastern Cooperative Oncology Group [ECOG] performance status 0-1). We studied CPI-613 in combination with modified FOLFIRINOX (oxaliplatin at 65 mg/m2, leucovorin a...Continue Reading

References

Mar 14, 2002·Journal of the American Chemical Society·Mohammad Movassaghi, Eric N Jacobsen
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George A Omura
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 14, 2009·Journal of the National Cancer Institute·Christophe Le TourneauLillian L Siu
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Jul 20, 2011·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Zuzana ZacharPaul M Bingham
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Aug 29, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Timothy S PardeeBayard L Powell
Jul 29, 2016·British Journal of Cancer·Muralidharan K ChllammaJennifer J Knox

❮ Previous
Next ❯

Citations

May 13, 2017·The Lancet Oncology·Christoph W MichalskiMarkus W Büchler
Mar 16, 2018·Future Oncology·Benjamin L Solomon, Ignacio Garrido-Laguna
Dec 8, 2017·Biomolecules & Therapeutics·Chi Van Dang, Jung-Whan Kim
May 13, 2018·Current Oncology Reports·Abdel Nasser Hosein, Muhammad Shaalan Beg
May 31, 2018·Cancer Chemotherapy and Pharmacology·Junko TaharaKatsutoshi Tokushige
Jul 12, 2018·Current Opinion in Oncology·Richa Bajpai, Mala Shanmugam
Aug 21, 2019·Cancers·Frank WeinbergDeepak Nagrath
Dec 17, 2019·Antioxidants & Redox Signaling·Natalie Y L NgoiAndrea L A Wong
Dec 17, 2019·Antioxidants & Redox Signaling·Jia Yu LeungReshma Taneja
Nov 11, 2019·Nature Reviews. Clinical Oncology·Christopher Nevala-PlagemannIgnacio Garrido-Laguna
Dec 4, 2019·Current Opinion in Pediatrics·Sameer H Issaq, Christine M Heske
Mar 19, 2020·Journal of Clinical Medicine·Sonia MissiroliCarlotta Giorgi
Jun 10, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Marloes ZoetemelkPatrycja Nowak-Sliwinska
Mar 18, 2020·Endocrine Reviews·Alexis Diaz-VegasSergio Lavandero
Dec 20, 2017·Expert Review of Anticancer Therapy·Anteneh A TesfayePhilip A Philip
May 7, 2020·International Journal of Molecular Sciences·Kinga B StopaMonika A Jakubowska
Apr 30, 2020·Journal of Experimental & Clinical Cancer Research : CR·Lixia GaoYong Teng
Jul 22, 2020·Cellular Oncology (Dordrecht)·Martin P OgrodzinskiSophia Y Lunt
Apr 13, 2019·Nature Reviews. Molecular Cell Biology·Jiajun Zhu, Craig B Thompson
May 30, 2019·Frontiers in Oncology·Monica NeaguAristidis M Tsatsakis
Apr 20, 2020·Drugs·Ritu Raj Singh, Eileen M O'Reilly
Jan 12, 2019·Frontiers in Oncology·Ali Vaziri-GoharJordan M Winter
May 16, 2020·Frontiers in Pharmacology·Ferda KaleağasıoğluMartin R Berger
Feb 26, 2019·Frontiers in Oncology·Ali Vaziri-GoharJordan M Winter
May 18, 2019·American Society of Clinical Oncology Educational Book·Salman Punekar, Daniel C Cho
Jul 10, 2020·Nature·Inmaculada Martínez-ReyesNavdeep S Chandel
Mar 10, 2020·F1000Research·Marc T RothJordan D Berlin
Aug 7, 2020·Biomedicines·Gabriela Reyes-CastellanosAlice Carrier
Oct 11, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miguel Quintela-FandinoSilvana Mouron
Jan 5, 2021·Chinese Medical Journal·Jin-Shou YangLei You
Dec 18, 2020·Frontiers in Oncology·Vincenza GranataFrancesco Izzo
Oct 24, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jiaqi LiAndrea L A Wong
Feb 28, 2021·Seminars in Oncology·Binbin Zheng-Lin, Eileen M O'Reilly
Feb 19, 2021·IScience·Hanne-Line RabbenChun-Mei Zhao
Mar 7, 2021·Seminars in Oncology·Aurélien LambertMichel Ducreux

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
exome sequencing

Clinical Trials Mentioned

NCT01835041

Software Mentioned

PRODIGE
WinNonLin

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.